PapersFlow Research Brief
Neurogenetic and Muscular Disorders Research
Research Guide
What is Neurogenetic and Muscular Disorders Research?
Neurogenetic and Muscular Disorders Research encompasses studies on the molecular genetics, gene therapies, and clinical management of conditions such as Spinal Muscular Atrophy (SMA), amyotrophic lateral sclerosis (ALS), and related motor neuron diseases, with a focus on genes like SMN1, SMN2, and C9ORF72.
This field includes 43,065 works on gene therapy, molecular genetics, and clinical management of SMA, covering SMN1 and SMN2 genes, Nusinersen treatment, antisense oligonucleotides, motor neuron pathology, and survival motor neuron protein. Key areas address therapeutic strategies like gene replacement therapy and small molecules to modulate SMN expression. Research also examines neuromuscular junction function and clinical outcomes in disorders like ALS and frontotemporal dementia (FTD).
Topic Hierarchy
Research Sub-Topics
SMN2 Splicing Modulation Therapies
Focuses on antisense oligonucleotides like Nusinersen that enhance SMN2 exon 7 inclusion to boost SMN protein levels. Clinical trials and molecular mechanisms are central to this research.
SMN1 Gene Replacement Therapy
Develops AAV-mediated delivery of functional SMN1 genes to motor neurons for SMA correction. Studies optimize vectors, dosing, and long-term efficacy in preclinical models.
Survival Motor Neuron Protein Function
Investigates SMN protein roles in snRNP biogenesis, mRNA splicing, and axonal mRNA transport. Research elucidates dosage-dependent pathology mechanisms.
SMA Motor Neuron Pathology
Examines selective vulnerability, degeneration cascades, and neuromuscular junction defects in SMA motor neurons. Includes ubiquitin-proteasome dysfunction and axonal transport studies.
SMA Clinical Management and Outcomes
Evaluates natural history, functional scales like CHOP-INTEND, and long-term prognosis post-therapy. Research develops standardized outcome measures for newborn screening era.
Why It Matters
Research in this area supports clinical management of SMA through treatments like Nusinersen, an antisense oligonucleotide targeting SMN2 to increase survival motor neuron protein levels. Gene replacement therapy aims to restore SMN1 function in SMA patients. Studies on C9ORF72 hexanucleotide repeats have identified causes of chromosome 9p-linked FTD and ALS, as shown in "Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS" by DeJesus‐Hernandez et al. (2011), with 4843 citations, and "A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD" by Renton et al. (2011), with 4358 citations. Identification of the SMA-determining gene in "Identification and characterization of a spinal muscular atrophy-determining gene" by Lefebvre et al. (1995) enabled targeted therapies, while ALS functional assessments via "The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function" by Cedarbaum et al. (1999) track disease progression in over 3200 cited works.
Reading Guide
Where to Start
"Identification and characterization of a spinal muscular atrophy-determining gene" by Lefebvre et al. (1995), as it establishes the foundational SMN1 gene discovery central to SMA genetics and therapy development.
Key Papers Explained
"Identification and characterization of a spinal muscular atrophy-determining gene" by Lefebvre et al. (1995) identified SMN1 as the SMA-determining gene, building the basis for therapies. "Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation" by Gurney et al. (1994) modeled ALS via SOD1 mutations, linking genetics to pathology. "Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS" by DeJesus‐Hernandez et al. (2011) and "A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD" by Renton et al. (2011) extended genetic insights to ALS-FTD overlap. "Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy" by Bodine et al. (2001) connected atrophy mechanisms to muscular disorders.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current work emphasizes gene replacement therapy and small molecule modulation of SMN expression for SMA, alongside clinical management with tools like ALSFRS-R. No recent preprints or news available, so frontiers remain in refining antisense oligonucleotides like Nusinersen and targeting C9ORF72 repeats.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C... | 2011 | Neuron | 4.8K | ✓ |
| 2 | A report: the definition and classification of cerebral palsy ... | 2007 | Developmental Medicine... | 4.8K | ✕ |
| 3 | A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of C... | 2011 | Neuron | 4.4K | ✓ |
| 4 | Motor Neuron Degeneration in Mice that Express a Human Cu,Zn S... | 1994 | Science | 4.1K | ✕ |
| 5 | Identification and characterization of a spinal muscular atrop... | 1995 | Cell | 3.9K | ✓ |
| 6 | Identification of Ubiquitin Ligases Required for Skeletal Musc... | 2001 | Science | 3.4K | ✓ |
| 7 | Bone marrow transplant | 1989 | Paediatric Care | 3.4K | ✕ |
| 8 | The ALSFRS-R: a revised ALS functional rating scale that incor... | 1999 | Journal of the Neurolo... | 3.2K | ✕ |
| 9 | Androgen receptor gene mutations in X-linked spinal and bulbar... | 1991 | Nature | 2.8K | ✕ |
| 10 | TDP-43 is a component of ubiquitin-positive tau-negative inclu... | 2006 | Biochemical and Biophy... | 2.7K | ✕ |
Frequently Asked Questions
What gene determines spinal muscular atrophy?
The SMN1 gene is the primary determinant of SMA, with mutations leading to reduced survival motor neuron protein. "Identification and characterization of a spinal muscular atrophy-determining gene" by Lefebvre et al. (1995) identified this gene, showing homozygous absence in SMA patients. SMN2 acts as a modifier by producing limited functional protein.
How do C9ORF72 repeats cause ALS and FTD?
A GGGGCC hexanucleotide repeat expansion in the noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. "Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS" by DeJesus‐Hernandez et al. (2011) first reported this in affected families. "A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD" by Renton et al. (2011) confirmed it across multiple cohorts.
What treatments target SMA?
Nusinersen, an antisense oligonucleotide, modulates SMN2 expression to increase survival motor neuron protein in SMA. Gene replacement therapy delivers functional SMN1 via viral vectors. These approaches address motor neuron pathology and neuromuscular junction defects central to SMA.
How is ALS progression measured?
The ALSFRS-R scale assesses respiratory function alongside motor abilities in ALS patients. "The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function" by Cedarbaum et al. (1999) validated this tool for clinical trials. It tracks disease advancement quantitatively.
What causes muscle atrophy in motor neuron diseases?
Ubiquitin ligases like MAFbx/Atrogin-1 and MuRF1 drive skeletal muscle atrophy, upregulated across models. "Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy" by Bodine et al. (2001) identified these via transcript profiling in rats. They mediate protein degradation during inactivity.
What is the role of SOD1 mutations in ALS?
Mutations in Cu,Zn superoxide dismutase (SOD1), such as G93A, cause motor neuron degeneration in familial ALS, affecting 20% of cases. "Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation" by Gurney et al. (1994) demonstrated this in transgenic mice. Enzyme activity remains largely intact despite the pathology.
Open Research Questions
- ? How can antisense oligonucleotides like Nusinersen be optimized for long-term SMN2 modulation in SMA?
- ? What mechanisms link C9ORF72 repeat expansions to selective motor neuron vulnerability in ALS-FTD?
- ? Which ubiquitin ligases beyond MAFbx and MuRF1 regulate muscle atrophy in SMA and ALS?
- ? How do TDP-43 aggregates contribute to neuromuscular junction failure in ALS?
- ? What small molecules most effectively upregulate SMN protein without off-target effects?
Recent Trends
The field comprises 43,065 works, with sustained focus on SMA genetics (SMN1/SMN2), Nusinersen, and gene replacement therapy.
Highly cited papers from 1994-2011 dominate, including DeJesus‐Hernandez et al. (2011, 4843 citations) on C9ORF72 in ALS-FTD and Lefebvre et al. (1995, 3908 citations) on SMA gene identification.
No recent preprints or news reported in the last 12 months.
Research Neurogenetic and Muscular Disorders Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neurogenetic and Muscular Disorders Research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers